Saturday, May 8, 2010

Free Online Quicktime Southpark

The alliance between big pharma and telecommunications companies.

.
Some 20,000,000 people unemployed in Europe. How do you give the child the iPill if we do not have a iPollo?.




France Telecom is a major business group, which according to data provided on its website had some results 2005 to 49,028 million euros, of which 960 were in the health sector: "Groupe France Télécom global CA 2005: 49,028 M € dont 960 M € dans le secteur de la santé." The foundation http://www.fundacionorange.es/fundacionorange/proyectos.html has initiated various projects of interest. There is no doubt that if capital and technology is applied to the field of pervasive developmental disorders and disability represent a breakthrough in the material resources available to make improvements varied.
.
However, when technical Healtcare Orange UK, France Telecom, make assumptions of what the future, a world of people predominantly aged, and a steady increase of people with disabilities, not just paint a rosy world.
.
So, if you rub their hands on the one hand, considering the great business opportunities that the medical sector with a similar population offered, with each patient in his house stuck next to a computer and a personal assistant or passing online medical consultation with a robot that can serve p.ejemplo, 12,587 medical consultations at the same time, something like the powerful computers make the big investment firms on Wall Street to buy and sell, they can forget the enormous enrichment of a few have inevitable reverse the impoverishment of many.
.
Beware, going to be that when they return home, to tell the millions who have won in a day, find a country that no longer exists or where you can not enjoy what you have. It enjoys more than a country where everyone has more or less enough and you can go down the street safe. The merger and concentration of capital impoverishes others elsewhere in the world or at home.
.
Pharmaceutical companies are beginning to approach the technology companies because they have difficulty proving the value of their drugs to governments and insurers. Using devices monitor patients in real time, pharmaceutical companies believe they can improve clinical outcomes and establish the relationship between costs and effectiveness of treatments.
.
The result, according to a report by Ernst & Young will be a new collaboration between laboratories and other firms in nontraditional areas such as IT, telecommunications and even retailers.
.
Some of these partnerships already in place. Novartis, for example, signed a $ 24 million last month with the U.S. Proteus Biomedical to create "smart pills" that can transmit data from inside the body to control the patient's vital signs and check if you take prescription drugs. Bayer developed a project to connect your meter for diabetic children, video game consoles Nintendo to promote consistent control of blood sugar levels. And unity
of Lifescan Johnson & Johnson has an application on the iPhone that allows users to download readings from the monitors that measure blood glucose via their phones Apple .
.
"We will see multiple types of collaborations the future, "Patrick told Reuters Flochel, head of life sciences at Ernst & Young, Europe, Middle East, India and Africa." This move will be driven by a goal on the results, with drug companies will have to compromise more and more, "he said. Other firms outside the industry looking to expectations these movements. Hofstraat Hans, president of corporate health electronics group Philips , said that drug delivery is an area in which technology companies can help. The Dutch group is working on delivery systems mediated by ultrasound and has a smart pill, or iPill , which can direct the drug to the appropriate point in the digestive tract. "We're a pharmaceutical company but would like to interact with the laboratories to provide solutions," he told a conference of pharmaceutical economics. The mobile phone company Orange , a unit of France Telecom has similar ambitions. Their interest is focused on communication with patients and chronic disease management, said Michael Reilly, director of Orange Healthcare UK, at the same meeting.
.
http://www.orange.com/en_EN/group/activities_key/health/ View . As manifested in the previous page, are the company's strategic objectives:
.
spearhead of France Telecom's strategy in the health sector.
.
aging population, an increasing number of people with dependency, increasing chronic diseases ... Such is the reality of the world around us. Based on our proven expertise in the health sector, Orange aims to become the market leader in e-health, meeting the needs of the market for health care and information technology and communication:
  • in the hospital, to improve comfort and access to patient information and simplify the work of medical equipment;

  • in the doctor's office, with remote monitoring disease chronic online appointment booking, "

  • in the patient's home, with solutions that provide hospital and home care.

The new era involves significant challenges, especially the cultural gap between the rapid advance of technology companies, with fast innovation cycles and the pharmaceutical industry, to launch a new product to market can take ten years or more. However, it seems worth trying. By following the clinical data and ensure that patients take the medicines at the right time, the laboratories could show the world that their products really work, which in turn justify their high prices. (See http://www.iblnews.com/story/53528 ).
.
In the next blog article will analyze the presence of Orange Foundation Guide for autism or Clinical Practice Guideline for the management of patients with disorders widespread development, recently published by GuíaSalud, fact explained by the tendency of the telecommunications companies to enter into a sector traditionally reserved for pharmaceutical companies, and vice versa.

0 comments:

Post a Comment